Cisplatin therapy for adenoid cystic carcinoma.
Adenoid cystic carcinoma of salivary gland origin is a relentless disease that produces a high rate of local recurrence, metastases, and death, regardless of the type of treatment. There have been few previous reports of effective chemotherapy. Cisplatin has been chosen for a trial in the treatment of patients with persistent, recurrent, or metastatic adenoid cystic carcinoma because of its demonstrated activity against a variety of tumor types, especially those with a low growth fraction. Ten patients have been included in a pilot study. Seventy percent of these patients have had a favorable subjective response and objective tumor regression. Further clinical trials are suggested.
D003528:Carcinoma, Adenoid Cystic / Q000188:drug therapy*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D009364:Neoplasm Recurrence, Local; D012468:Salivary Gland Neoplasms / Q000188:drug therapy*
D002945:Cisplatin